Skip to main content
. 2017 Jan;102(1):79–84. doi: 10.3324/haematol.2016.149765

Figure 1.

Figure 1.

Survival of 344 patients with primary myelofibrosis (PMF). (A) Overall survival of PMF patients with high (≥50%) and low (<50%) JAK2V617F allele burden. (B) Overall survival (OS) of PMF patients according to mutation status. (C) Overall survival of PMF patients with favorable and adverse mutation status. Patients with either high JAK2V617F allele burden, mutated CALR, or mutated MPL had a better OS than patients with low JAK2V617F allele burden or triple-negative mutation status. (D) Overall survival according to patients’ age (over or under 65 years of age). (E) OS of patients with PMF based on risk stratification according to age and mutation status.